Precision Medicine
-
Most hospital, health systems see increase in genomics, genetics vendors by 2023, report finds
The new report, from the University of Pittsburgh Medical Center’s Center for Connected Medicine, surveyed 101 representatives of hospitals and healthcare systems. Nine out of 10 respondents said they were providing genomic or genetic testing or planning to.
-
Delivering on the promise of precision cancer medicine and why it matters even more during a pandemic
While many of us have avoided exposure to Covid-19 by sheltering in place, patients with […]
-
How are healthcare organizations shifting to digital documents?
In order to gain insight into how organizations are thinking about digitizing medical documents and the strategy behind those decisions, we’re conducting a brief survey of the MedCity News audience and will publish a report based on this survey’s findings.
-
StartUPDATES: New developments from healthcare startups
Read about new developments from healthcare startups including HealCo, Eikonoklastes, Sidecar Health and more.
-
Founders’ story: Seven Bridges
A Q&A with executives from Seven Bridges, a bioinformatics analysis business, highlights the company’s work in the precision medicine sector.
-
Founders’ story: Libera Bio
In an interview with MedCity News, the founder and CSO of Spanish biotech startup Libera Bio talked about her company’s ambitions to apply its precision medicine technologies for the treatment of different types of cancer.
-
A snapshot of the precision medicine landscape
What needs to happen to facilitate data sharing, ensure access to genome sequencing and promising personalized therapies?
-
Artificial Intelligence, BioPharma
Precision medicine startup Notable starts trial to test AI platform in blood cancer patients
The ANSWer trial will enroll up to 1,000 patients and follow them for up to a year. A smaller feasibility study conducted with Stanford University and Tempus showed an 84% accuracy rate in predicting patient responses to drugs.
-
Startups, Artificial Intelligence
UC Health’s chief data scientist has some advice for startups thinking about stealth mode
Startups being in stealth mode is a fairly common phenomenon but is that helpful in the healthcare world where trust and transparency are key?
-
FDA approves Blueprint Medicines’ precision therapy for rare form of gastrointestinal cancer
The agency on Thursday approved Ayvakit (avapritinib) for gastrointestinal stromal tumor, or GIST, that harbors a PDGFRa exon 18 mutation. Still, identifying patients could be the biggest challenge, an analyst wrote.
-
Bristol Myers Squibb SVP Ho Sung Cho highlights pioneering work with protein degradation in support of drug development
In a podcast with MedCity News, Cho talked about the company’s profile in the San Diego life science ecosystem, the need to fail fast and frequently in the early stages of drug development and the work BMS is doing to combat Covid-19.
-
Foresight is 2020: A look at what’s ahead for biopharma
Executives from biopharma companies and an academic expert weigh in on what’s in store for areas like cell and gene therapy, precision medicine and drug pricing.
-
Health IT, MedCity Influencers
IT will be key to precision medicine’s success in 2020
Unless IT concerns related to precision medicine are addressed, healthcare will simply reenact a mistake made years ago with EHRS valuable data that can directly impact care will be locked in a silo, unavailable during clinical decision-making.
-
4 healthcare innovation events that should be on your radar in 2020
As you map out your communication and marketing goals for 2020, keep this roster of MedCity healthcare innovation events in mind.
-
Health IT, MedCity Influencers
Data: The central component of precision medicine
Realizing the full potential of precision medicine starts with finding better ways to collect, share and make decisions based on data.
-
Syapse, Pfizer enter deal to develop precision medicine in oncology
The New York-based drugmaker marks the third major biopharma company to partner with the San Francisco-based firm, after Amgen and Roche.
-
How best to describe precision medicine beyond oncology? ‘It’s complicated.’
While well-developed in cancers, precision medicine’s readiness for prime time beyond oncology varies markedly from disease to disease. But reimbursement remains a significant hurdle.
Promoted
How Presbyterian Is Using Digital Health Tools to Address Pandemic Challenges
Timing is everything. In the case of Presbyterian Healthcare Services, its adoption of the Bright.MD platform in 2017 to facilitate telehealth appointments was fortuitous. Read now to learn more.
